📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Novartis AG

Common Name
Novartis
Country
Switzerland
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75,883
Ticker
NOVN
Exchange
SIX SWISS EXCHANGE
Description
Novartis AG is a global healthcare company that operates in the pharmaceuticals and biotechnology sectors. Its primary function is to research, develop, and manufacture healthcare products, with a foc...

Novartis's GHG Emissions Data Preview

In 2024, Novartis completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Novartis has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=NOVN&reporting_period=2024"

Verified Sources Behind Novartis’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Novartis’s data sources below and access millions more through our Disclosure Search.

a. Novartis's ESG Data Spreadsheet 2024
a. Novartis's ESG Data Spreadsheet 2024
b. Novartis's Sustainability Data Spreadsheet 2019
b. Novartis's Sustainability Data Spreadsheet 2019
c. Novartis's ESG Data Spreadsheet 2021
c. Novartis's ESG Data Spreadsheet 2021

Insights into Novartis's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions ofNovartis amounted to407,400metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Novartisdecreased by 8.65%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Novartis's Scope 1 Emissions Over Time

2019202020212022202320240150 k300 k450 k600 ktCO2e-22%-27%-5%-5%-18%
  • Total Scope 1
  • Year-over-Year Change

What are Novartis's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Novartis were 207,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

Has Novartis reduced its Scope 1 emissions over time?

Since 2019, Novartis's Scope 1 emissions have decreased by 57.28%, reflecting a declining long-term trend in Scope 1 emissions over time.ab

Compared to the previous year(2023), Novartis's Scope 1 emissions decreased by 17.56%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Novartis's Scope 2 emissions?

In 2024, Novartis reported Scope 2 greenhouse gas (GHG) emissions of 30,000 tCOâ‚‚e using the market-based method and 200,400 tCOâ‚‚e using the location-based method.a

Has Novartis reduced its Scope 2 emissions over time?

Since 2019, Novartis's Scope 2 greenhouse gas (GHG) emissions (Location-Based)have decreased by 56.14%, reflecting a declining long-term trend in Scope 2 emissions over time.ac

Compared to the previous year(2023), Novartis's Scope 2 emissions(Location-Based) have remained relatively stable, indicating that Novartis's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Novartis use for Scope 2 reporting?

In 2024, Novartis reported its Scope 2 emissions using the market-based method and using the location-based method.a

Novartis's Scope 2 Emissions Over Time

2019202020212022202320240150 k300 k450 k600 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Novartis's Value Chain Emissions

In 2024, Novartis reported 4,350,300 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Novartis includes a breakdown across 12of the 15 Scope 3 categories defined by the GHG Protocol,matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Novartis's Scope 3 Emissions Over Time

20192020202120222023202402 M4 M6 M8 MtCO2e+20%-36%+7%-8%-5%
  • Total Scope 3
  • Year-over-Year Change

What are Novartis's Scope 3 emissions?

In 2024, Novartis reported total Scope 3 emissions of 4,350,300 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

Approximately 95.77%of these emissions originated from upstream activities such as purchased goods and capital goods, while 4.23%came from downstream activities like product use, distribution, and end-of-life treatment.a

Has Novartis reduced its Scope 3 emissions over time?

Since 2019, Novartis's Scope 3 emissionshave decreased by 28.1%, reflecting a declining long-term trend in Scope 3 emissions over time.ab

Compared to the previous year (2023), Novartis's Scope 3 emissions remained relatively stable, indicating that Novartis's emissions have plateaued with no significant change in its value chain footprint.a

What categories of Scope 3 emissions does Novartis disclose?

In 2024, Novartis reported emissions for 12 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This reflects a high level of granularity and transparency in the company's emissions reporting.

What are the main sources of Novartis's Scope 3 emissions?

In 2024, the largest contributors to Novartis's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 3,372,500 tCOâ‚‚e(77.52%)
  • Capital Goods (Cat. 2): 195,700 tCOâ‚‚e(4.5%)
  • Upstream Transportation and Distribution (Cat. 4): 166,000 tCOâ‚‚e(3.82%)

Novartis's Scope 3 Emissions by Categories

UpstreamTransportation andDistribution(Cat. 4)(3.8%)Purchased Goods andServices (Cat. 1)(77.5%)Capital Goods(Cat. 2)(4.5%)

Insights into Novartis’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Novartis reported Scope 1 greenhouse gas (GHG) emissions of 207,000 tCOâ‚‚e and total revenues of USD 41,706 millions. This translates into an emissions intensity of 4.96 tCOâ‚‚e per millions USD.a

Novartis's Scope 1 Emissions Intensity Compared to Peers

1002,00050,000500,00010,000,000Scope 1 Emissions (tCO2e)1005005,00020,000200,000Revenues (Millions of USD)SZTOBristol-Myers SquibbYear: 2024Scope 1: 206,726 tCO2eRevenue: $M 48,300Scope 1 Intensity: 4.28 tCO2e/$MSSSanofi IndiaYear: 2024Scope 1: 510 tCO2eRevenue: $M 232Scope 1 Intensity: 2.20 tCO2e/$MGilead SciencesYear: 2024Scope 1: 53,856 tCO2eRevenue: $M 28,754Scope 1 Intensity: 1.87 tCO2e/$MCosmo PharmaceuticalsYear: 2024Scope 1: 5,658 tCO2eRevenue: $M 260Scope 1 Intensity: 21.74 tCO2e/$MSanten PharmaceuticalYear: 2024Scope 1: 17,372 tCO2eRevenue: $M 1,994Scope 1 Intensity: 8.71 tCO2e/$MBiogenYear: 2024Scope 1: 56,611 tCO2eRevenue: $M 9,676Scope 1 Intensity: 5.85 tCO2e/$MMerck KGaAYear: 2024Scope 1: 858,053 tCO2eRevenue: $M 22,015Scope 1 Intensity: 38.98 tCO2e/$MOno PharmaceuticalYear: 2024Scope 1: 8,100 tCO2eRevenue: $M 3,319Scope 1 Intensity: 2.44 tCO2e/$MKalbe FarmaYear: 2024Scope 1: 19,895 tCO2eRevenue: $M 2,028Scope 1 Intensity: 9.81 tCO2e/$MZZZhangzhou Pientzehuang PharmaceuticalYear: 2023Scope 1: 2,301 tCO2eRevenue: $M 1,415Scope 1 Intensity: 1.63 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MOtsuka HoldingsYear: 2024Scope 1: 368,733 tCO2eRevenue: $M 14,840Scope 1 Intensity: 24.85 tCO2e/$MAmgenYear: 2024Scope 1: 147,000 tCO2eRevenue: $M 33,424Scope 1 Intensity: 4.40 tCO2e/$MVirbacYear: 2024Scope 1: 10,966 tCO2eRevenue: $M 1,454Scope 1 Intensity: 7.54 tCO2e/$MAstellas PharmaYear: 2024Scope 1: 52,212 tCO2eRevenue: $M 10,589Scope 1 Intensity: 4.93 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2024Scope 1: 8,517 tCO2eRevenue: $M 3,835Scope 1 Intensity: 2.22 tCO2e/$MOrganon & CoYear: 2024Scope 1: 34,200 tCO2eRevenue: $M 6,403Scope 1 Intensity: 5.34 tCO2e/$MAbbVieYear: 2024Scope 1: 300,072 tCO2eRevenue: $M 56,334Scope 1 Intensity: 5.33 tCO2e/$MDaiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MGSKYear: 2024Scope 1: 521,000 tCO2eRevenue: $M 39,374Scope 1 Intensity: 13.23 tCO2e/$MRoche HoldingYear: 2024Scope 1: 245,832 tCO2eRevenue: $M 68,903Scope 1 Intensity: 3.57 tCO2e/$MSichuan Kelun PharmaceuticalYear: 2024Scope 1: 2,361,763 tCO2eRevenue: $M 2,989Scope 1 Intensity: 790.21 tCO2e/$MTTTong Ren Tang TechnologiesYear: 2024Scope 1: 30,000 tCO2eRevenue: $M 1,086Scope 1 Intensity: 27.62 tCO2e/$MKyowa KirinYear: 2024Scope 1: 16,133 tCO2eRevenue: $M 3,157Scope 1 Intensity: 5.11 tCO2e/$MOOOrion OyjYear: 2024Scope 1: 5,625 tCO2eRevenue: $M 1,605Scope 1 Intensity: 3.50 tCO2e/$MNovartisYear: 2024Scope 1: 207,000 tCO2eRevenue: $M 41,706Scope 1 Intensity: 4.96 tCO2e/$M

How does Novartis's GHG emissions intensity compare to its peers?

In 2024, Novartis reported a Scope 1 emissions intensity of 4.96 tCOâ‚‚e per millions USD. Compared to the peer group median of 5.34, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Novartis rank on GHG emissions intensity within its industry?

In 2024, Novartis ranked 11 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a

Novartis is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Novartis's Total Carbon Footprint

In 2024, Novartis reported a total carbon footprint of 4,757,700 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.22% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Novartis's total carbon footprint was Scope 3 emissions, accounting for 91.44% of the company's total carbon footprint, followed by Scope 1 emissions at 4.35%.a

Want Full Access to Novartis's GHG Emissions Dataset?
Sign Up